Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26709646 | 1.00 | RECQL (0.48) | RECQLSMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL66695 | 0.84 | RECQL (0.44) | RECQLSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL16497835 | 0.84 | RECQL (0.44) | RECQLSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL66696 | 0.84 | RECQL (0.44) | RECQLSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL4609843 | 0.84 | RECQL (0.44) | RECQLSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL18986974 | 0.83 | HTR2A (0.42) | RECQLSMN1; SMN2LMNAHTR2AFUCA1 | |
| SCHEMBL760251 | 0.83 | HTR2A (0.42) | RECQLSMN1; SMN2LMNAHTR2AFUCA1 | |
| SCHEMBL12371117 | 0.83 | HTR2A (0.42) | RECQLSMN1; SMN2LMNAHTR2AFUCA1 | |
| SCHEMBL20799630 | 0.83 | RECQL (0.45) | RECQLSMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL10522832 | 0.82 | PTPN1 (0.48) | RECQLSMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105221-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | RECQL 2119/4885SMN1; SMN2 3394/4885ALDH1A1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.